CAJ | 학술논문

目的：观察S1联合低剂量多西紫杉醇治疗进展期胃癌的疗效及安全性。方法我院2012年01月-2013年10月共20例进展期胃癌，行s160mg口服 bidd1-14天，多西紫杉醇针40mg/m2静脉滴注 d1治疗，21天重复。2周期评价疗效。结果全组都可评价疗效，中位os12.2月，PFS 5个月，疾病控制率（CR+PR+SD）达40%。主要不良反应为1-2级中性粒细胞减少及1级胃肠反应。结论 S1联合低剂量多西紫杉醇治疗进展期胃癌有效、安全。可作为进展期胃癌的治疗选择。
목적：관찰S1연합저제량다서자삼순치료진전기위암적료효급안전성。방법아원2012년01월-2013년10월공20례진전기위암，행s160mg구복 bidd1-14천，다서자삼순침40mg/m2정맥적주 d1치료，21천중복。2주기평개료효。결과전조도가평개료효，중위os12.2월，PFS 5개월，질병공제솔（CR+PR+SD）체40%。주요불량반응위1-2급중성립세포감소급1급위장반응。결론 S1연합저제량다서자삼순치료진전기위암유효、안전。가작위진전기위암적치료선택。
Obejective To evaluate the effect and toxicity of S1 combined with low dose Docetaxel in patients of advanced gastric cancer .methods Twenty patients of advanced gastric cancer were treated with combination therapy of S1 60mg bid on days 1 through 14 plus Docetaxel 40mg/m2 day 1,every 21 days.The evaluation of efficacy and toxicity was achieved in performed after every 2 cycles .Resuit Al 20 patients assessed for efficacy and toxicity. The disease control was 40%,The common toxicities of the regimen included myelosuppression and gastrointestinal reactions.Conclusions The regimen of S1 plus Docetaxel is effective against advanced gastric cancer with acceptable toxicity.